AIM ImmunoTech Email Format
Pharmaceutical ManufacturingFlorida, United States11-50 Employees
AIM ImmunoTech is a pharmaceutical company focused on research and development of therapeutics aimed at treating various cancers and immune-deficiency disorders. Its work centers on nucleic acids and natural interferon to bolster the body's antiviral defenses and support the development of treatments for cancer and chronic diseases, with Ampligen (rintatolimod) and Alferon N Injection (Interferon Alfa-N3) as its flagship products. The company operates a manufacturing facility in New Brunswick, New Jersey, and maintains a headquarters presence in Ocala, Florida, while pursuing partnerships to advance the commercial potential of its therapies. AIM ImmunoTech has engaged in clinical and preclinical work and has pursued regulatory and development activity for Ampligen in areas such as cancer and ME/CFS, and holds an approved indication for Alferon N Injection in Argentina for certain infections, with ongoing interest in broader applications. Recent activity includes collaborations and presentations at industry events and partnerships aimed at advancing its cancer and immunotherapy programs.